Objective:To investigate the clinical and prognostic signiifcance of EphA2 expression in diffuse large B-cell lymphoma (DLBCL). Methods:Immunohistochemistry for EphA2/CD10/Bcl-6/MUM-1 was performed on tissue sections from 51 patients diagnosed with DLBCL, and its correlation with clinicopathologic variables of patients was assessed using Pearson’s χ2 test or Fisher’s exact test when necessary. The survival was analyzed by Kaplan-Meier method. Results:High expression of EphA2 was detected in patients of lower clinical stage (P=0.001), better international prognostic index (IPI) score (P = 0.020) and germinal center B-cell (GCB) phenotype (P = 0.000). It was also correlated with the expression of CD10 (P = 0.001) and MUM-1 (P=0.001). Conclusion:EphA2/CD10/MUM1 might contribute to sub-classiifcation of DLBCL.